Ruxolitinib Cream

Ruxolitinib cream 1.5% (Opzelura, Incyte) is a topical JAK inhibitor that blocks JAK1 and JAK2. These enzymes carry the inflammatory and itch signals behind Atopic Dermatitis. It is a steroid-free alternative to Topical Corticosteroids and Topical Calcineurin Inhibitors. In September 2025 the FDA extended it to children aged 2–11 (Medscape, citing the September 2025 label). The current US label (June 2026) allows “short-term and non-continuous chronic treatment” of mild-to-moderate AD in non-immunocompromised patients aged 2 and over. The disease must not be adequately controlled by topical prescription therapies, or those therapies must be inadvisable. It is therefore a second-line option, not a first cream for a toddler.

Ruxolitinib Cream [part-of] JAK Inhibitors Ruxolitinib Cream [treats] Atopic Dermatitis FDA [regulates] Ruxolitinib Cream

Evidence: TRuE-AD3. This phase 3, double-blind trial (Eichenfield et al., JAAD 2025) randomised 330 North American children aged 2–11 with mild-to-moderate AD. Inclusion required an IGA of 2–3 and 3–20% of body surface area affected. Children were randomised 2:2:1 to 0.75% cream, 1.5% cream or vehicle twice daily for 8 weeks. IGA treatment success (clear or almost clear, with at least a 2-grade improvement) was reached by 56.5% on 1.5% and 36.6% on 0.75%, versus 10.8% on vehicle. Itch and quality of life also improved. In the 167 children aged 2–6 (the toddler and preschool end), success was 60.6% on 1.5% versus 15.2% on vehicle. Treatment-related adverse events were 5.9–7.6% versus 3.0%, with no serious events. The evidence level is moderate: one well-run industry-funded RCT with only 8 weeks of controlled data. There is no head-to-head comparison with a mild steroid or Tacrolimus. Enrolment was limited to North America.

Ruxolitinib Cream [treats] Itch-Scratch Cycle Ruxolitinib Cream [relates] Crisaborole

Safety and the boxed warning. The label carries the full JAK-class boxed warning: serious infections, mortality, malignancy, major cardiovascular events and thrombosis. It was extrapolated mainly from oral JAK inhibitors in adults over 50 with rheumatoid arthritis (FDA Drug Safety Communication, 2021). In TRuE-AD3, the adverse reactions more common than vehicle were upper respiratory infections (15% vs 11%), application-site reactions (5% vs 2%), fever (2% vs 0%) and decreased white cell count (2% vs 0%). Application-site reactions, fever and low white cell counts were reported more often in 2–11-year-olds than in older patients. Children with low blood counts at screening were excluded, so the effect in that group is unknown. In juvenile rats, oral ruxolitinib affected growth and bone (including fractures at high doses). The effects were worse when dosing started earlier in life. Combining the cream with biologics such as Dupilumab, other JAK inhibitors or strong immunosuppressants is not recommended.

FDA [regulates] JAK Inhibitors Ruxolitinib Cream [relates] Dupilumab

Application-area limits matter more in small children

For ages 2–11 the US label allows a thin layer twice daily to at most 20% of body surface area, and no more than one 60 g tube every 2 weeks. Do not use under occlusion: no wet wraps or bandages over it (Wet Wrap Therapy). Stop when the itch and rash clear, and see the doctor again if there is no improvement by 8 weeks. Toddlers with widespread eczema may exceed the 20% limit, so it suits limited patches, not whole-body flares.

Licensing outside the US and parent reports. The European Medicines Agency licenses Opzelura for AD in adults only (plus vitiligo from 12 years), so there is no EU paediatric eczema indication. It is not part of NICE CG57 or the South African Eczema Guidance. Under-2s are excluded everywhere. On r/Mommit, one parent reported that a dermatologist-prescribed ruxolitinib cream cleared their child’s eczema “in days” (evidence: anecdotal).

European Medicines Agency [regulates] Ruxolitinib Cream

Conflict: [FDA Opzelura label, 2025–2026] licenses ruxolitinib cream for mild-to-moderate AD from age 2. [EMA Opzelura EPAR, accessed 2026] licenses it for AD in adults only. This is a regulatory difference on the same TRuE trial evidence, not contradictory data. Unresolved — add to open_questions.

Licensing update (Oct 2026). The FDA label (effective 30 June 2026) still sets the age floor at 2 years, with the same limits (≤20% of body surface, short-term, non-continuous use). No approval below 2 years was found, although the AAD Pediatric Guideline 2026 manuscript called a younger-age approval “imminent”. The EU EPAR (updated 3 August 2026) and the UK SmPC (PLGB 42338/0021, revised 11 September 2026) still license Opzelura for AD in adults only. The AAD 2026 paediatric guideline makes a strong recommendation for ruxolitinib cream from age 2, on moderate-certainty evidence. It advises considering other options first in children with risk factors for serious infection, cancer, thrombosis or cardiovascular events.

AAD Pediatric Guideline 2026 [supports] Ruxolitinib Cream

Connections

• JAK Inhibitors — topical member; US ≥2 y, EU adults only, source: FDA Opzelura label 2026; EMA EPAR
• Crisaborole — alternative non-steroid topical, source: FDA labels
• FDA — Sept 2025 approval for ages 2–11; class boxed warning, source: FDA label 2026
• European Medicines Agency — adult-only AD licence, source: EMA EPAR
• Topical Calcineurin Inhibitors — other steroid-free second-line option, source: FDA label 2026
• Wet Wrap Therapy — occlusion not permitted, source: FDA label 2026
• Dupilumab — combination with biologics not recommended, source: FDA label 2026
• Atopic Dermatitis — TRuE-AD3 IGA success 56.5% vs 10.8% in ages 2–11, source: Eichenfield JAAD 2025
• AAD Pediatric Guideline 2026 — strong rec ≥2 y; ≤20% BSA, source: JAAD 2026; labels re-checked Oct 2026